Hormone Therapy Balance and Risk of Over-Adjustment

Understanding Hormone Balance in Different Clinical Contexts

The U.S. Preventive Services Task Force recommends against using menopausal hormone therapy for primary prevention of chronic conditions due to moderate magnitude of adverse consequences including increased stroke, venous thromboembolism, and breast cancer (with combined estrogen-progestin therapy) 1
The American College of Physicians suggests that the lowest effective dose for the shortest duration should be used when treating menopausal symptoms, as recommended by various guideline societies 2
Over-adjustment manifests as increased cardiovascular risk, thromboembolism, and breast cancer rather than simply "too much estrogen" 1

Target serum testosterone levels should be within typical cisgender male reference ranges for masculinizing therapy 3, 4
Over-adjustment risks include polycythemia, reduced HDL cholesterol, androgenic alopecia, acne, and potentially increased myocardial infarction risk 3, 4
Under-adjustment fails to suppress menses and achieve desired masculinization 3, 4
Hemoglobin increases to male reference range within 3 months—monitoring is essential 3, 4
Optimal estradiol doses/concentrations for feminization remain unclear, but local laboratory menopausal levels using high-sensitivity assays should guide therapy 5
Over-adjustment with estrogen increases risk of venous thromboembolism, ischemic stroke, and myocardial infarction 6

Treatment must account for menopausal status with careful attention to ovarian estrogen production 5
Sequential hormone therapy continues as long as benefit is demonstrated without rapid visceral progression 5
Fulvestrant should use 500-mg dosing with loading schedule for optimal efficacy 5

Baseline assessment for gender-affirming hormone therapy should include complete blood count, liver function, lipid profile, glucose, baseline hormone levels, and cardiovascular risk factors 6
Initial follow-up at 3 months to check estradiol and testosterone levels 6
Regular monitoring every 3-6 months during first year, then annually if stable 6
Mental health benefits include 20% decrease in depression and 16% improvement in quality of life scores after 1 year 6

Treating menopausal women with hormone therapy as if achieving specific estradiol levels is the goal—symptom relief at lowest effective dose is the actual target 1
Failing to monitor for polycythemia in transgender men on testosterone, which can significantly increase cardiovascular risk 3, 4
Using peripheral androgen receptor antagonists (spironolactone, bicalutamide) in transgender women without recognizing these may not lower testosterone concentrations despite blocking androgen effects 3, 4
Discontinuing gender-affirming hormone therapy due to concerns about side effects without recognizing this significantly worsens gender dysphoria and mental health outcomes 6